Download PDF
Thromb Haemost 1999; 82(02): 298-304
DOI: 10.1055/s-0037-1615846
Research Article
Schattauer GmbH

Proteolysis, Cell Adhesion, Chemotaxis, and Invasiveness Are Regulated by the u-PA-u-PAR-PAI-1 System

Francesco Blasi
1   Dipartimento di Ricerca Biologica e Tecnologica ( DIBIT), Università Vita-Salute San Raffaele, Milano, ITALY
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

Introduction

High levels of urokinase-type plasminogen activator (u-PA), of its inhibitor (plasminogen activator inhibitor (PAI)-1), or of its receptor (u-PAR, CD87) are strong prognostic indicators of relapse in human cancers. In addition, many in vitro data show that u-PA, PAI-1, and u-PAR have a profound influence on cell migration. This set of molecules regulates surface proteolysis, cell adhesion, and chemotaxis through different mechanisms. Binding to u-PAR strongly stimulates the activation of pro-u-PA and, hence, of plasminogen, resulting in localized production of the broad-spectrum serine protease, plasmin, which can digest extracellular matrix proteins or activate latent motogenic factors. Chemotaxis is induced through an u-PA-dependent conformational change in u-PAR, which uncovers a very potent chemotactic epitope(s) that acts through a pertussis toxin-sensitive step and activates intracellular tyrosine kinases. In addition, cell adhesion is affected by an u-PA-dependent exposure of u-PAR epitope(s), which interact with vitronectin (VN), integrins, and caveolin, thus modifying the substrate specificity. Thus, u-PA binding can transform u-PAR from a simple receptor for u-PA into a pleiotropic ligand for other surface molecules.

All of these processes are regulated by the u-PA inhibitor, PAI-1. Inhibition of cell adhesion and migration by PAI-1 on VN occurs because the same region of VN is required for interaction with PAI-1, u-PAR, and integrins. PAI-1, however, also affects u-PAR occupancy by triggering the internalization of the u-PA-u-PAR complex, the degradation of u-PA, and the recycling of free u-PAR. Available data suggest that cells respond to a “stop” signal, due to the PAI-1-dependent internalization and degradation of u-PA. Cells also respond to a “go” signal through the stimulation of surface-proteolysis, exposure of chemotactic epitopes, and recycling of u-PAR to novel surface positions. Finally, cells respond to a “pause” signal through transient u-PAR-dependent adhesion stages, thus shifting the cells between an “adhesion-mode” and a “migration-mode.”

 

  • References

  • 1 Danø K, Andreasen PA, Grøndal-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 1985; 44: 139-266.
    PubMedSearch in Google Scholar
  • 2 Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: a new target for anti-metastatic therapy?. T Pharmacol Sci. 1994; 15: 25-29.
    PubMedSearch in Google Scholar
  • 3 Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med. 1996; 2: 1174-1178.
    CrossrefPubMedSearch in Google Scholar
  • 4 Blasi F. u-PA, u-PAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?. Immunol Today. 1997; 18: 415-419.
    CrossrefPubMedSearch in Google Scholar
  • 5 Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72: 1-22.
    CrossrefPubMedSearch in Google Scholar
  • 6 Rømer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996; 2: 287-292.
    CrossrefPubMedSearch in Google Scholar
  • 7 Carmeliet P, Collen D. Genetic analysis of the plasminogen and coagulation system in the mice. Haemostasis. 1996; (Suppl. 04) 132-153.
    PubMedSearch in Google Scholar
  • 8 Waltz DA, Chapman Jr. HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994; 269: 14746-14750.
    PubMedSearch in Google Scholar
  • 9 Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman Jr. HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994; 269: 32380-32388.
    PubMedSearch in Google Scholar
  • 10 Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman Jr. HA. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
    CrossrefPubMedSearch in Google Scholar
  • 11 Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996; 15: 1572-1582.
    PubMedSearch in Google Scholar
  • 12 Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990; 88: 1-19.
    PubMedSearch in Google Scholar
  • 13 Cubellis MV, Wun T-C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990; 9: 1079-1085.
    PubMedSearch in Google Scholar
  • 14 Jensen PH, Christensen EI, Ebbesen P, Gliemann J, Andreasen PA. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Regul. 1990; 1: 1043-1056.
    CrossrefPubMedSearch in Google Scholar
  • 15 Nykjær A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thøgersen HC, Munch M, Andreasen PA, Gliemann J. Purified α2 macroglobulin receptor/LDL receptor related protein binds urokinase-plasminogen activator inhibitor type-1 complex. Evidence that the α2 macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992; 267: 14543-14546.
    PubMedSearch in Google Scholar
  • 16 Conese M, Nykjær A, Christensen EI, Paetersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Blasi F. Alpha-2 macroglobulin receptor-dependent internalization of the urokinase receptor. J Cell Biol. 1995; 131: 1609-1622.
    CrossrefPubMedSearch in Google Scholar
  • 17 Nykjær A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor during internalization of the u-PA-serpin complexes. EMBO J. 1997; 16: 2610-2620.
    CrossrefPubMedSearch in Google Scholar
  • 18 Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J Clin Invest. 1996; 97: 1818-1826.
    CrossrefPubMedSearch in Google Scholar
  • 19 Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB. Induction of primary cutaneous melanocytic neoplasms in utokinase-type plasminogen activator (u-PA)-deficient and wild type mice: cellular blue nevi invade but do not progress to malignant melanoma in u-PA-deficient animals. Cancer Res. 1996; 56: 3597-3604.
    PubMedSearch in Google Scholar
  • 20 Pedersen TL, Yong K, Pedersen JO, Hansen NE, Danø K, Plesner T. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal hemoglobinuria. Br J Haematol. 1996; 95: 45-51.
    PubMedSearch in Google Scholar
  • 21 May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta-2 integrins in vivo. J Exp Med. 1998; 188: 1029-1037.
    CrossrefPubMedSearch in Google Scholar
  • 22 Bayou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenik NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998; 4: 923-928.
    CrossrefPubMedSearch in Google Scholar
  • 23 Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 1994; 8 (Suppl. 01) 189-203.
    PubMedSearch in Google Scholar
  • 24 Bergman BL, Scott RW, Bajpai A, Watts S, Baker JB. Inhibition of tumor-cell-mediated destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci USA. 1986; 83: 996-1000.
    CrossrefPubMedSearch in Google Scholar
  • 25 Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 1991; 51: 274-281.
    PubMedSearch in Google Scholar
  • 26 Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface bound urokinase. J Cell Biol. 1988; 107: 2437-2445.
    CrossrefPubMedSearch in Google Scholar
  • 27 Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA. 1993; 90: 5021-5025.
    CrossrefPubMedSearch in Google Scholar
  • 28 Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992; 11: 4825-4833.
    PubMedSearch in Google Scholar
  • 29 Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-beta by co-cultures of pericytes and smooth muscle cells: a self-regulating system. J Cell Biol. 1990; 111: 757-763.
    CrossrefPubMedSearch in Google Scholar
  • 30 Gudewicz PW, Bilboa N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun. 1987; 147: 1176-1181.
    CrossrefPubMedSearch in Google Scholar
  • 31 Boyle MD, Chiodo VA, Lawman MJ, Gee AP, Young M. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol. 1987; 139: 169-174.
    PubMedSearch in Google Scholar
  • 32 Fibbi G, Ziche M, Morbidelli L, Magnelli L, Del Rosso M. Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res. 1988; 179: 385-395.
    CrossrefPubMedSearch in Google Scholar
  • 33 Odekon LE, Sato Y, Rifkin D. Urokinase-type plasmionogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol. 1992; 150: 258-263.
    CrossrefPubMedSearch in Google Scholar
  • 34 Pepper MS, Sappino AP, Stöcklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 1993; 122: 673-684.
    CrossrefPubMedSearch in Google Scholar
  • 35 Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol. 1994; 126: 259-270.
    CrossrefPubMedSearch in Google Scholar
  • 36 Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest. 1994; 93: 1380-1387.
    CrossrefPubMedSearch in Google Scholar
  • 37 Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990; 111: 783-792.
    CrossrefPubMedSearch in Google Scholar
  • 38 Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis. 1988; 2: 73-84.
    PubMedSearch in Google Scholar
  • 39 Blasi F, Conese M, Møller LB, Pedersen N, Cavallaro U, Cubellis MV, Fazioli F, Hernandez Marrero L, Limongi P, Muñoz-Canoves P, Resnati M, Riittinen L, Sidenius N, Soravia E, Soria MR, Stoppelli MP, Talarico D, Teesalu T, Valcamonica S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis. 1994; 8 (Suppl. 01) 182-187.
    PubMedSearch in Google Scholar
  • 40 Ellis V, Plough M. Structure-function relationship in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom a-neurotoxins. FEBS Lett. 1994; 349: 163-168.
    CrossrefPubMedSearch in Google Scholar
  • 41 Besser D, Verde P, Nagamine Y, Blasi F. Signal transduction and the u-PA/u-PAR system. Fibrinolysis. 1996; 10: 215-237.
    PubMedSearch in Google Scholar
  • 42 Pöllänen J, Saksela O, Salonen EM, Andreasen P, Nielsen L, Danø K, Vaheri A. Distinct localization of urokinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol. 1987; 104: 1085-1096.
    CrossrefPubMedSearch in Google Scholar
  • 43 Pöllänen J, Vaheri A, Tapiovaara H, Riley E, Bertram K, Woodrow G, Stephens RW. Prourokinase activation on the surface of human rhabdomyosarcoma cells: Localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl Acad Sci USA. 1990; 87: 2230-2234.
    CrossrefPubMedSearch in Google Scholar
  • 44 Hébert CA, Baker JB. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol. 1988; 106: 1241-1247.
    CrossrefPubMedSearch in Google Scholar
  • 45 Myöhänen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem. 1993; 41: 1291-1301.
    CrossrefPubMedSearch in Google Scholar
  • 46 Degryse B, Resnati M, Rabbani A, Villa A, Fazioli F, Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood. In press.
    PubMed
  • 47 Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997; 16: 7279-7389.
    CrossrefPubMedSearch in Google Scholar
  • 48 Picone R, Kajtaniak E, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Danø K, Blasi F. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol. 1989; 108: 693-702.
    CrossrefPubMedSearch in Google Scholar
  • 49 Bianchi E, Ferrero E, Fazioli F, Mangili F, Wang J, Bender JR, Blasi F, Pardi R. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest. 1996; 98: 1133-1141.
    CrossrefPubMedSearch in Google Scholar
  • 50 Nusrat AR, Chapman Jr. HA. An autocrine role for urokinase in phorbol-ester mediated differentiation of myeloid cell lines. J Clin Invest. 1991; 87: 1091-1097.
    CrossrefPubMedSearch in Google Scholar
  • 51 Waltz DA, Sailor LZ, Chapman Jr. HA. Cytokines induce urokinase-dependent adhesion of human myeloid cell: a regulatory role for plasminogen activator inhibitors. J Clin Invest. 1993; 91: 1541-1552.
    CrossrefPubMedSearch in Google Scholar
  • 52 Rao NK, Shi G-P, Chapman Jr. HA. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest. 1995; 96: 465-474.
    CrossrefPubMedSearch in Google Scholar
  • 53 Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs the urokinase receptor-mediated cell adhesion and release?. J Cell Biol. 1996; 134: 1563-1571.
    CrossrefPubMedSearch in Google Scholar
  • 54 Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996; 224: 344-353.
    CrossrefPubMedSearch in Google Scholar
  • 55 Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Rønne E, Kobzik L, Chapman Jr. HA. (1996). Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-3184.
    PubMedSearch in Google Scholar
  • 56 Simon DI, Ezratty AM, Francis SA, Rennke H, LoScalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood 1993; 82: 2414-2422.
    PubMedSearch in Google Scholar
  • 57 Bohuslav J, Horejsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, beta-2 integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995; 181: 1381-1390.
    CrossrefPubMedSearch in Google Scholar
  • 58 Xue W, Kindzelskii AL, Todd III RF, Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol. 1994; 152: 4630-4640.
    PubMedSearch in Google Scholar
  • 59 Kindzelskii AL, Laska ZO, Todd III RF, Petty HR. Urokinase-type plasminogen activator reversibly dissociates from complemenbt receptor type 3 (?Mb2,CD11b/CD18) during neutrophil polarization. J Immunol. 1996; 157: 297-3099.
    PubMedSearch in Google Scholar
  • 60 Springer TA, Anderson DC. The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis and migration into inflammatory sites: insights from an experiment in nature. In: Evered D, Nugent J, O’Connor M. eds. Biochemistry of Macrophages (Ciba Foundation Symposium 118). Pittman; London: 1986: 102-126.
    Search in Google Scholar
  • 61 Yebra M, Parry GCN, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J Biol Chem. 1996; 271: 29393-29399.
    CrossrefPubMedSearch in Google Scholar
  • 62 Cubellis MV, Andreasen PA, Ragno P, Mayer M, Danø K, Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA. 1989; 86: 4828-4832.
    CrossrefPubMedSearch in Google Scholar
  • 63 Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989; 108: 1987-1995.
    CrossrefPubMedSearch in Google Scholar
  • 64 Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectin. Nature 1996; 383: 441-443.
    CrossrefPubMedSearch in Google Scholar
  • 65 Kjøller L, Kanse SM, Kirkegaard T, Rodenburg E, Rønne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 1997; 232: 420-429.
    CrossrefPubMedSearch in Google Scholar
  • 66 Reilly Jr. JJ, Chapman Jr HA. Association between macrophage plasminogen activator activity and lung function in young cigarette smokers. Am Rev Resp Dis. 1988; 138: 1422-1428.
    PubMedSearch in Google Scholar
  • 67 Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman Jr. HA. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med. 1995; 322: 890-895.
    PubMedSearch in Google Scholar
  • 68 Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase to peripheral blood cells. Thromb Haemost. 1987; 58: 936-942.
    Thieme ConnectPubMedSearch in Google Scholar
  • 69 Gyetko MR, Libre EA, Fuller JA, Chen G-H, Toews GB. Urokinase is required for T lymphocytes proliferation and activation in vitro. J Lab Clin Med. 1999; 133: 274-288.
    CrossrefPubMedSearch in Google Scholar
  • 70 Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996; 56: 2428-2435.
    PubMedSearch in Google Scholar
  • 71 Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 1983; 35: 611-619.
    CrossrefPubMedSearch in Google Scholar
  • 72 Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 1988; 48: 1270-1277.
    PubMedSearch in Google Scholar
  • 73 Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase plasminogen activator receptyor in human squamous cell carcinoma on malignancy. EMBO J. 1994; 13: 3983-3991.
    PubMedSearch in Google Scholar
  • 74 Conforti G, Dominguez-Jimenez C, Ronne E, Hoyer-Hansen G, Dejana E. Cell surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cells monolayer. Blood 1994; 83: 994-1105.
    PubMedSearch in Google Scholar
  • 75 Sølberg H, Rømer J, Brünner N, Holm A, Sidenius N, Danø K, Høyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer. 1994; 58: 877-881.
    CrossrefPubMedSearch in Google Scholar
  • 76 Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem. 1997; 243: 21-26.
    CrossrefPubMedSearch in Google Scholar
  • 77 Lund RL, Rømer J, Rønne E, Ellis V, Blasi F, Danø K. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor b1 in human A549 lung carcinoma cells. EMBO J. 1991; 10: 3399-3407.
    PubMedSearch in Google Scholar
  • 78 Danø K, Rømer J, Nielson BS, Bjørn S, Pyke C, Rygaard J, Lund LR. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. Acta Pathol Microb Scand 1999; 107: 120-127.
    PubMedSearch in Google Scholar